metformin has been researched along with Fibrodysplasia Ossificans Progressiva in 1 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lin, H | 1 |
| Ying, Y | 1 |
| Wang, YY | 1 |
| Wang, G | 1 |
| Jiang, SS | 1 |
| Huang, D | 1 |
| Luo, L | 1 |
| Chen, YG | 1 |
| Gerstenfeld, LC | 1 |
| Luo, Z | 1 |
1 other study available for metformin and Fibrodysplasia Ossificans Progressiva
| Article | Year |
|---|---|
AMPK downregulates ALK2 via increasing the interaction between Smurf1 and Smad6, leading to inhibition of osteogenic differentiation.
Topics: Activin Receptors, Type I; AMP-Activated Protein Kinase Kinases; Cell Differentiation; Fibroblasts; | 2017 |